Innate Pharma S.A. (LON:0EVI)
London flag London · Delayed Price · Currency is GBP · Price in EUR
1.419
+0.021 (1.50%)
At close: Feb 12, 2026

Innate Pharma Ratios and Metrics

Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
115132183234295245
Market Cap Growth
-15.12%-27.85%-21.67%-20.77%20.59%-38.25%
Enterprise Value
8786141163209129
Last Close Price
1.241.582.222.963.663.11
PS Ratio
10.667.953.434.5814.243.92
PB Ratio
26.1818.114.074.873.271.75
P/TBV Ratio
26.1818.114.105.025.562.49
EV/Sales Ratio
7.875.152.653.1910.072.07
EV/EBITDA Ratio
-----10.86
EV/EBIT Ratio
-----133.87
EV/FCF Ratio
-2.45-----
Debt / Equity Ratio
5.253.510.770.780.410.12
Debt / EBITDA Ratio
-----1.33
Net Debt / Equity Ratio
-6.41-5.63-1.01-1.09-0.70-0.85
Net Debt / EBITDA Ratio
0.660.996.164.931.75-9.96
Net Debt / FCF Ratio
0.806.831.603.011.272.52
Asset Turnover
0.100.140.330.250.090.20
Quick Ratio
2.082.503.513.211.673.64
Current Ratio
2.212.603.733.381.733.81
Return on Equity (ROE)
-271.37%-162.91%-14.28%-71.75%-34.53%-0.44%
Return on Assets (ROA)
-25.92%-22.52%-4.23%-4.40%-10.40%0.19%
Return on Invested Capital (ROIC)
----122.70%-173.03%5.30%
Return on Capital Employed (ROCE)
-79.80%-66.10%-9.30%-10.40%-25.50%0.40%
Earnings Yield
-34.20%-30.93%-3.58%-22.02%-15.02%-23.41%
FCF Yield
-30.64%-4.56%-15.58%-7.46%-16.89%-19.27%
Buyback Yield / Dilution
-4.15%-0.74%-1.02%-0.12%-0.77%-17.97%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.